Published in PLOS Biology · View the paper (DOI)
Researchers at Yale School of Medicine have discovered a new drug compound, TC-2153, that inhibits the negative effects of STEP protein, which is key to regulating learning and memory in Alzheimer's disease. Decreasing STEP levels reversed cognitive deficits in mice, suggesting a potential therapeutic approach for treating the condition.